載入...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Na minha lista:
| 主要作者: | |
|---|---|
| 格式: | Artigo |
| 語言: | Russo |
| 出版: |
ABV-press
2021-09-01
|
| 叢編: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| 主題: | |
| 在線閱讀: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|